Reticulogen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reticulogen

Reticulogen is a pharmaceutical preparation historically defined as an antianemic agent that functions as a concentrated source of the essential B vitamin, Cobalamin. Its composition as an injectable solution, combining a purified vitamin with biological factors, is clinically recognized for effectively bypassing common nutrient absorption challenges.

Property Description
Active ingredient Cyanocobalamin, Liver extract derived factors
Form Injection solution (Parenteral)
Pharmacological class Vitamin, Nutritional supplement, Antianemic preparation
Common purpose Supports red blood cell production and nerve health
Origin Derived biological extract and synthetic compound

What Type of Medicine is Reticulogen?

Reticulogen is classified as an antianemic preparation and a nutritional supplement within the therapeutic category of vitamins. Its primary ingredient, Cyanocobalamin, belongs to the essential water-soluble B Vitamins group, required for numerous metabolic functions. The product components are recognized as belonging to the vitamin class. Developed by Eli Lilly, this formulation gained distinction for its early use as a source of the active Anti-pernicious anemia factor.


The Composition of Reticulogen: Active Ingredients and Origin

The identity of Reticulogen is rooted in its components: the synthetic form of Vitamin B12, Cyanocobalamin, combined with essential co-factors historically derived from a refined parenteral liver extract. This specific formulation is a pioneering combination product, utilizing both the isolated synthetic vitamin and supportive agents from a biological extract. The product is manufactured as an injection solution intended for the parenteral route of administration, which is critical for individuals who cannot absorb the vitamin adequately through normal intestinal means.


Primary Purpose: Supporting Blood and Nerve Health

The principal function of Reticulogen is to supply the indispensable nutrient required for fundamental biological integrity. The provided Vitamin B12 is essential for hematopoiesis, supporting the critical process of red blood cell maturation in the bone marrow. This foundational role ensures that blood production is maintained, while the nutrient also acts as a vital coenzyme for specific metabolic pathways necessary for healthy nerve tissue function.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Reticulogen?

Possible side effects and safety information

The safety profile for Reticulogen, a parenteral Cyanocobalamin (Vitamin B12) preparation, is structured around the officially documented risks as detailed in government regulatory labels. The primary safety concerns are categorized by frequency and the organ systems affected.


System-Organ Classes and Frequency

Side effects are classified across several System-Organ Classes (SOC) in regulatory documents. Reactions affecting the Skin and Subcutaneous Tissue Disorders (such as transient rash or itching) and Gastrointestinal Disorders (mild, transient diarrhea) are among the effects occasionally reported. Localized pain or soreness at the injection site is a common and expected reaction due to the parenteral route of administration.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights rare but clinically significant serious adverse reactions. These include severe hypersensitivity reactions, such as anaphylactic shock and death, which have been reported with parenteral Vitamin B12. Concerns related to the Cardiovascular Disorders include the risk of pulmonary edema or the exacerbation of congestive heart failure, particularly in individuals with pre-existing heart disease, noted as occurring early in treatment.

Use of this medicine is contraindicated in patients with a documented history of sensitivity to Vitamin B12 or cobalt. Furthermore, official labeling specifies that this type of preparation must not be used in individuals with Leber’s disease (hereditary optic nerve atrophy) due to the risk of severe and swift optic nerve damage. Treatment may also unmask symptoms of other hematological conditions, such as Polycythemia vera.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the official guidance on overdose for Reticulogen, an injectable preparation containing Cyanocobalamin, based strictly on government regulatory documents.

Official Overdose Profile

Feature Regulatory Statement
Documented Overdose Manifestations Overdosage has not been reported for this drug in regulatory documents; acute symptoms are unlikely to manifest due to its low acute toxicity.
Serious Outcomes No severe or life-threatening outcomes are specifically documented as a result of acute overdose in regulatory overdose sections.
Antidote Information No specific antidote is known for the active ingredient.
Supportive Management Treatment is based on providing symptomatic and supportive treatment.

Immediate Actions Required

Regulatory documentation mandates that patients or caregivers seek immediate medical attention for a suspected overdose of Reticulogen. This urgent action is required regardless of the substance's low acute toxicity profile, ensuring professional monitoring and evaluation.

Due to the nature of the drug as a water-soluble vitamin, excess amounts of the component are typically eliminated rapidly via renal excretion. This factor underlies the official statement that treatment for overexposure is unlikely to be needed; however, seeking medical care for any suspected event is the required regulatory action.

Therapeutic Uses of Reticulogen

What Reticulogen Treats: Main Uses and Benefits

Reticulogen is a prescription medicine approved to manage specific conditions that involve nutritional deficiencies. The core therapeutic application is to address deficiencies required for the adequate production of blood components, which can lead to various forms of anemia. Using this medicine helps individuals manage symptoms that may include physical weakness, general tiredness, and pale skin associated with an inadequate supply of essential nutrients.

The clinical areas where Reticulogen is typically utilized involve: the replacement therapy for pernicious anemia, certain types of megaloblastic anemias, and other deficiency states where nutrient replenishment is medically indicated. The goal of treatment is to provide relief from the symptomatic presentation of the deficiency.


Quick Fact: Addresses Nutrient Deficiency

The medicine supports the body's capability to maintain typical blood cell function in individuals experiencing clinically documented nutrient depletion, aiding in the resolution of associated constitutional symptoms.

Eligibility and Restrictions for Use

Who can and cannot use Reticulogen?

Reticulogen (Cyanocobalamin Injection) is officially approved for individuals diagnosed with a Vitamin B12 deficiency resulting from malabsorption syndromes, such as Pernicious Anemia or conditions following gastrectomy. Eligibility is defined by specific exclusions and population restrictions detailed in regulatory documentation.


Contraindicated Populations

This medicine must not be used by certain groups, representing an absolute prohibition:

  • Patients with documented Hypersensitivity to Cobalt or Vitamin B12.
  • Individuals diagnosed with early Leber's disease (hereditary optic nerve atrophy).
  • Newborns and premature infants when the formulation contains the preservative Benzyl Alcohol.

Conditional Use and Restrictions

Official labeling requires caution or limited use for the following populations:

  • Organ Function: Patients with Impaired Kidney Function should use the medicine with caution due to the potential risk of aluminum accumulation with prolonged parenteral use.
  • Age: Older Adults require cautious dose selection due to the higher frequency of decreased hepatic or renal function in this age group.
  • Reproductive Status: For pregnant women, use is conditional (Category C) and is administered only if clearly needed, reflecting the absence of adequate safety studies. Nursing mothers must also exercise caution, as the vitamin is excreted in human milk.

What should I know about interactions with other medicines?

This section outlines interaction patterns for Reticulogen as documented in regulatory sources. Co-administration is formally contraindicated in patients with a known hypersensitivity to Cobalt or the active ingredient, Cyanocobalamin. Use is also restricted in individuals with early Leber's disease (hereditary optic nerve atrophy) due to the risk of severe aggravation of optic atrophy.

Interactions are primarily categorized as pharmacodynamic interference. Chloramphenicol may blunt the expected therapeutic response to Reticulogen by interfering with blood cell production. Concomitant use of high-dose Folic Acid carries the risk of masking hematological signs of deficiency while potentially allowing irreversible neurological damage to advance. Additionally, several agents, including various antibiotics, methotrexate, and pyrimethamine, may invalidate diagnostic blood assays used to determine Vitamin B12 levels.

Regarding exposure, oral contraceptives have been associated with lowered serum concentrations of Cyanocobalamin. The therapeutic efficacy may also be impaired by coexisting conditions such as infection or uremia. In terms of substances, heavy chronic alcohol intake is documented to cause malabsorption, an effect relevant to the overall efficacy of this antianemic treatment. Renal impairment is a population-specific consideration due to the risk of Aluminum accumulation from the injection formulation.

Mechanism of Action

Reticulogen's function is centered on supplying Cobalamin (Vitamin B12) as a cofactor replacement for two distinct enzyme systems that regulate DNA synthesis and metabolic pathways. The parenteral delivery ensures systemic availability by bypassing the intrinsic factor-mediated gastrointestinal absorption mechanism.

Correcting DNA Precursor Availability and Cell Maturation

The mechanism involves activation of the enzyme Methionine Synthase (MTR) using the active coenzyme Methylcobalamin. This activation is crucial because it regulates Tetrahydrofolate (THF), the specific folate form required for synthesizing the bases of DNA. By enabling the synthesis of DNA precursors, this domain resolves the deficit in cell division, facilitating maturation of progenitor cells in the bone marrow.

Metabolic Integrity and Myelin Sheath Support

The second pathway involves activating the enzyme L-methylmalonyl-CoA mutase (MUT) with the coenzyme 5-deoxyadenosylcobalamin. This action facilitates the metabolic clearance of methylmalonic acid (MMA), a metabolite that mediates myelin sheath disruption. This mechanism maintains the functional stability of the MUT pathway, regulating metabolic processes that influence nerve tissue structure.

Dosage and Administration Information

Administration Overview

Reticulogen is a parenteral medication intended for deep intramuscular injection. This method of administration ensures that the active components are absorbed into the systemic circulation through the muscle tissue. The procedure is typically performed by a healthcare professional in a clinical setting to ensure proper technique and placement.

Preparation and Handling

The solution should be inspected visually for particulate matter or discoloration prior to administration. The preparation involves using a sterile syringe and needle to withdraw the required volume from the vial. It is important to maintain aseptic technique throughout the process to prevent contamination.

Injection Site Selection

Common sites for deep intramuscular injection include the upper outer quadrant of the gluteus maximus or the deltoid muscle. Rotating the injection site for subsequent administrations is a standard practice to minimize local tissue irritation and promote optimal absorption.

Clinical Monitoring

Healthcare providers monitor the patient's response to the medication through periodic blood tests, specifically looking at reticulocyte counts and other hematological parameters. These observations help in assessing how the body is utilizing the medication. Observations of the injection site for any localized reactions are also part of the standard follow-up care.

Recent Clinical Evidence

Evidence for Use in Vitamin B12 Deficiency and Anemia

Reticulogen is a pharmaceutical preparation that was studied for its role as a replacement therapy in conditions characterized by fluctuating or episodic manifestations of B12 deficiency, such as pernicious anemia and megaloblastic anemia. The research supporting this use includes foundational clinical trials and historical research that explored the use of parenteral Cobalamin (Vitamin B12) replacement therapy for these conditions.

These studies included adult populations with documented deficiencies resulting from impaired nutrient absorption due to underlying gastrointestinal conditions. Research examined both the immediate and short-term consequences of therapy, including historical comparative trials against liver extracts or other antianemic factors. Findings describe patterns observed in the studies related to the correction of the deficiency; studies describe observed changes in blood production, such as shifts in red blood cell parameters.

The evidence contributes to understanding how patients reported their experience and how their blood components evolved in the observed populations, with regulatory documents contributing to the broader evidence landscape.


Types of Studies and Outcomes Examined

The studies that form the evidence landscape for Reticulogen are broad, spanning from foundational historical comparative trials to more recent systematic reviews of parenteral Cobalamin administration. These studies were evaluated in research exploring short-term symptom changes and metabolic responses.

The research examined specific, measurable endpoints beyond simply tracking symptoms. Studies focused on biomarkers of deficiency, such as levels of Methylmalonic Acid and Homocysteine, which data show patterns related to metabolic changes following treatment. Researchers also measured key hematological parameters like the reticulocyte count, which contributes to understanding short-term changes in the bone marrow's red blood cell production activity. For patients facing neurological concerns, the research describes attempts to monitor outcomes related to systemic or functional imbalance, specifically tracking neurological status to track deterioration.


Long-Term Treatment and Maintenance Research

For conditions marked by functional limitations, such as pernicious anemia, which typically require ongoing treatment, research explored research scenarios involving long-term administration. The long-term research scenario involves observing responses over defined time intervals and often includes follow-up data spanning many years.

Findings indicate that sustained, continuous administration may be needed to maintain corrected hematological status and prevent the return of deficiency markers. This evidence contributes to the broader evidence landscape by describing what has been observed so far in patients requiring ongoing treatment. However, the evidence contributes to understanding symptom patterns over extended periods primarily through observational settings rather than modern long-term Randomized Controlled Trials (RCTs) designed for maintenance.


Evidence Gaps and Research Limitations

While the evidence describes research scenarios involving the use of parenteral Cobalamin for deficiency, several limitations remain. Comparative evidence is lacking between the specific combination formulation of Reticulogen (Cyanocobalamin plus liver derived factors) and modern, single-ingredient Cobalamin injection alternatives.

Furthermore, data for certain groups remain insufficient, and follow-up durations were limited in many of the trials that examined short-term changes. Existing studies provide limited insight into the optimal dose and frequency for maintenance therapy for all patients, meaning dosing protocols often reflect established clinical practice rather than evidence from recent, large-scale studies. The research primarily focuses on laboratory results (biochemical endpoints), and information on patient-reported outcomes describing perceived discomfort or daily functioning appears to be less consistently reported.

Key Studies & References Vitamin B12 Deficiency: Etiology, Pathophysiology, and Clinical Features (NIH StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Reticulogen (FAQ)

Q: Is Reticulogen used to treat other things besides its main purpose?

A: Reticulogen is officially approved and indicated for the treatment of Vitamin B12 deficiency. This deficiency is typically caused by conditions where the vitamin cannot be properly absorbed, such as pernicious anemia or after certain gastrointestinal surgeries. Use outside of these officially approved indications is not addressed in the product's regulatory documents.

Q: Does Reticulogen start working right away, or does it take a few weeks?

A: Official product information describes that the initial treatment phase uses daily injections designed to rapidly replenish the body's vitamin reserves. Changes in blood production, one measure of therapeutic effect, are monitored early in treatment. Observed individual responses to treatment are known to vary.

Q: Can Reticulogen interact with common over-the-counter pain relievers?

A: Regulatory documents listing drug interactions typically do not include common over-the-counter pain relievers like acetaminophen or ibuprofen as having significant interactions with the active ingredient in Reticulogen. Healthcare professionals advise discussing all medications, including non-prescription pain relievers, with your provider.

Q: Are there any known food interactions with Reticulogen?

A: The official product information does not list major food interactions. However, regulatory documents indicate that high doses of Vitamin C supplements may interfere with the available amount of Vitamin B12, leading to specific discussion with a provider.

Q: Is it okay to take Reticulogen if I have high blood pressure?

A: Regulatory warnings mention a risk of pulmonary edema or the worsening of congestive heart failure, particularly early in treatment with Vitamin B12 injections. A healthcare provider will consider the presence of pre-existing conditions, such as high blood pressure, when assessing these potential risks.

Q: Does Reticulogen affect how blood tests are read?

A: Official labeling states that certain other agents, such as some antibiotics and chemotherapy drugs, may invalidate diagnostic blood assays used to measure Vitamin B12 levels. Reticulogen itself is a replacement vitamin, but the presence of other medications may interfere with the testing process.

Q: How does Reticulogen differ from other drugs that treat the same condition?

A: Reticulogen is described as a combination product. It contains the synthetic form of Vitamin B12 (Cyanocobalamin) along with supportive factors historically derived from a parenteral liver extract. This specific dual composition distinguishes it from products that contain only single-ingredient Vitamin B12.

Q: Does Reticulogen cause fatigue or changes in energy levels?

A: While the medicine's purpose is to correct the fatigue associated with Vitamin B12 deficiency, some serious adverse reaction reports have included mentions of unusual tiredness or weakness. Any unexpected change in symptoms should be discussed with the prescribing healthcare professional.

Q: Can Reticulogen cause weight gain or weight loss?

A: Regulatory documents list weight gain as an effect that has been reported with the medicine, sometimes associated with fluid retention or swelling. Weight loss is not typically highlighted in the official safety information.

Q: What should I do if I think Reticulogen isn't working for me?

A: Official guidance describes consulting with a healthcare professional as the appropriate step when questions arise about the medicine's expected benefit, or if any unusual problems are experienced.

Q: Does Reticulogen have an expiration date, and how strict is it?

A: As with all pharmaceutical products, Reticulogen has an expiration date clearly printed on the label and packaging. This date indicates the time through which the manufacturer guarantees the product's full potency and safety when it is stored under the correct conditions.

Q: Is there a generic version of Reticulogen available?

A: Reticulogen is a specific brand name formulation. However, the active ingredient, Cyanocobalamin injection, is widely approved and available as a generic product in many regions.

Q: Why did my doctor prescribe Reticulogen instead of Drug X?

A: The decision to prescribe a specific brand, formulation, or type of drug is a clinical judgment. It is based on the prescribing healthcare professional's assessment of the patient's individual needs, the characteristics of the specific product, and established clinical treatment guidelines.

Q: Does Reticulogen interact with alcohol?

A: Official documents note that heavy chronic alcohol intake over a prolonged period may impair the absorption of Vitamin B12. While Reticulogen is an injection that bypasses absorption issues, this effect of alcohol is relevant to the underlying condition being treated.

Q: Can I take other vitamins with Reticulogen?

A: There is specific regulatory caution regarding the concurrent use of high-dose Folic Acid and high-dose Vitamin C supplements due to potential interference. Regulatory guidance includes informing a healthcare professional about all vitamins and nutritional supplements being taken.

Q: Is there a special diet required when taking Reticulogen?

A: Official labeling advises patients with pernicious anemia who follow a vegetarian diet (containing no animal products) that they may need to take oral B12 supplements regularly. This is because their diet does not provide the vitamin that the body cannot absorb.

Q: Are there ongoing clinical trials for new uses of Reticulogen?

A: While the initial research supporting this specific drug is foundational, the broader scientific and medical community continues to study Vitamin B12 (Cobalamin) replacement therapy. New research and clinical trials are ongoing to define optimal treatment strategies and potential new applications.

Q: Are there any restrictions on driving or operating machinery while taking Reticulogen?

A: Regulatory documents list side effects such as dizziness, and less commonly, confusion or drowsiness. Official information indicates that if these effects are experienced, caution is warranted, as they could potentially impact the ability to drive or operate machinery safely.

Q: If Reticulogen is stopped, do the effects wear off quickly?

A: Official guidance warns patients with pernicious anemia that failure to continue with the required monthly injections will result in the return of anemia. Importantly, it can also lead to the development of serious and potentially irreversible nerve damage.

Q: Why is Reticulogen considered a long-term treatment?

A: Reticulogen is considered a long-term treatment, often for the patient's life, because conditions like pernicious anemia cause a chronic, permanent inability to absorb the necessary vitamin from food. Ongoing monthly replacement therapy is essential to prevent relapse and maintain nerve and blood cell health.

Q: I feel dizzy after starting Reticulogen; is this normal?

A: Dizziness is listed among the symptoms that have been reported in association with the medicine, although it is typically described as uncommon. Official information suggests that any new or worsening symptom, including dizziness, is a topic for discussion with the prescribing healthcare professional.

Q: Is it possible to take too much Reticulogen?

A: The official labeling does include an Overdosage section. The active ingredient, Vitamin B12, is a water-soluble vitamin. In cases of excessive administration, amounts of the vitamin not needed by the body are typically and quickly excreted through the urine.

Q: How quickly should I expect to see an effect from Reticulogen?

A: Official product information describes that the initial treatment phase uses daily injections designed to rapidly replenish the body's vitamin reserves. Changes in blood production, one measure of therapeutic effect, are monitored early in treatment. Observed individual responses to treatment are known to vary.

How should Reticulogen be stored and disposed of?

How to Store and Dispose of Reticulogen

Proper storage and handling of Reticulogen (Cyanocobalamin) are essential for maintaining its stability and effectiveness, based on regulatory labeling. Both the injection and intranasal spray forms must be stored at Controlled Room Temperature, which is typically defined between 20 C and 25 C (68 F and 77 F), with limited excursions permitted.

Storage Requirements

Attribute Requirement
Temperature Controlled Room Temperature (15 C to 30 C)
Light/Handling Protect from light; Do not freeze (especially the intranasal spray)
Container Keep in original container to protect from external factors

Disposal Guidelines

Products that have been exposed to improper storage conditions, such as temperature extremes or contamination, must be discarded and shall not be salvaged or returned for use. Disposal must be conducted according to established regulatory procedures for non-salvageable drug products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reticulogen found in:

A-Z Index: